News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care L.A. McKeown May 17, 2024
News Daily News Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI Michael O'Riordan May 02, 2024
News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Daily News Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2 Michael O'Riordan June 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022